Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer
Primary Purpose
Unresectable Pancreatic Cancer
Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Bilateral Thoracoscopic Splanchnicectomy
Sponsored by
About this trial
This is an interventional supportive care trial for Unresectable Pancreatic Cancer
Eligibility Criteria
Inclusion Criteria:
- Must be 18 years of age
- Diagnosed with stage III/IV pancreatic cancer
- Willing and able to comply with the protocol requirements
- Able to comprehend and have signed the Informed Consent Form (ICF) to participate in the study
Exclusion Criteria:
- Participating in another clinical trial for the treatment of cancer at the time of screening
- Pregnant or currently breast feeding
Sites / Locations
- University of Louisville
- Greenville Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
BTS Intervention
No BTS Intervention
Arm Description
Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.
Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.
Outcomes
Primary Outcome Measures
Abdominal pain
Pain will be measured using a visual analog pain score
Daily Narcotic Requirements
Narcotic usage will be monitored at each follow-up visit
Secondary Outcome Measures
Quality of Life Assessment
Quality of Life will be measured using the SF-12® Patient Questionnaire
Presence of Nausea
Patients will be queried about the presence of nausea using a questionnaire
Presence of Reflux
Patients will be queried about the presence of reflux using a questionnaire
Use of Anti-emetics
anti-emetic dosage will be measures at each follow-up visit
Full Information
NCT ID
NCT03117556
First Posted
April 7, 2017
Last Updated
June 17, 2021
Sponsor
University of Louisville
Collaborators
Norton Healthcare
1. Study Identification
Unique Protocol Identification Number
NCT03117556
Brief Title
Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer
Official Title
Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Withdrawn
Why Stopped
no subjects enrolled
Study Start Date
August 31, 2017 (Actual)
Primary Completion Date
April 16, 2018 (Anticipated)
Study Completion Date
April 16, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Louisville
Collaborators
Norton Healthcare
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to compare the efficacy of bilateral thoracoscopic splanchnicectomy (BTS) to conventional narcotic analgesia for control of abdominal pain in patients with pancreatic ductal adenocarcinoma not amenable to surgical resection.
Detailed Description
All patients with unresectable pancreatic cancer will be considered for participation in this study. Patients with locally advanced or metastatic cancer that meet inclusion criteria will be randomized into one of two arms, treatment with BTS and narcotic analgesia or treatment with narcotic analgesia alone. After randomization a baseline pain score will be assessed using the visual analog pain scale. Narcotic dosage and frequency will be evaluated at the time of enrollment. A pre-treatment quality of life score will be recorded using the SF-12® Patient Questionnaire. Patients will also be queried about the presence of nausea and reflux.
After all baseline assessments are complete patients will be taken to the OR to undergo their assigned procedure. BTS and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. BTS will be performed as described in the study procedure. Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only. An evaluation will be completed postoperatively in which the length of stay, post-op complications, and chest X-ray results will be recorded. Follow-up assessments will be conducted 24-48 hours post-procedure and at the time of discharge. Further follow-up assessments will be conducted 14 days, 30 days, and 90 days post-procedure during an office visit with the clinical research team or medical oncology.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Unresectable Pancreatic Cancer
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
All patients with unresectable pancreatic cancer will be considered for participation in this study. Patients with locally advanced or metastatic cancer that meet inclusion criteria will be randomized into one of two arms, treatment with BTS and narcotic analgesia or treatment with narcotic analgesia alone.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
BTS Intervention
Arm Type
Experimental
Arm Description
Bilateral thoracoscopic splanchnicectomy and infusaport placement will be performed on patients randomly selected for treatment with BTS and narcotic analgesia. Narcotics will still be prescribed for pain as needed.
Arm Title
No BTS Intervention
Arm Type
No Intervention
Arm Description
Patients chosen to be treated with narcotic analgesia alone will undergo infusaport placement only.
Intervention Type
Procedure
Intervention Name(s)
Bilateral Thoracoscopic Splanchnicectomy
Intervention Description
BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
Primary Outcome Measure Information:
Title
Abdominal pain
Description
Pain will be measured using a visual analog pain score
Time Frame
1 year
Title
Daily Narcotic Requirements
Description
Narcotic usage will be monitored at each follow-up visit
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Quality of Life Assessment
Description
Quality of Life will be measured using the SF-12® Patient Questionnaire
Time Frame
1 year
Title
Presence of Nausea
Description
Patients will be queried about the presence of nausea using a questionnaire
Time Frame
1 year
Title
Presence of Reflux
Description
Patients will be queried about the presence of reflux using a questionnaire
Time Frame
1 Year
Title
Use of Anti-emetics
Description
anti-emetic dosage will be measures at each follow-up visit
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Must be 18 years of age
Diagnosed with stage III/IV pancreatic cancer
Willing and able to comply with the protocol requirements
Able to comprehend and have signed the Informed Consent Form (ICF) to participate in the study
Exclusion Criteria:
Participating in another clinical trial for the treatment of cancer at the time of screening
Pregnant or currently breast feeding
Facility Information:
Facility Name
University of Louisville
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Greenville Memorial Hospital
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29605
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
IPD will not be shared with other researchers.
Citations:
PubMed Identifier
23622135
Citation
Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013 Jun;144(6):1252-61. doi: 10.1053/j.gastro.2013.01.068.
Results Reference
background
PubMed Identifier
18506917
Citation
Gachago C, Draganov PV. Pain management in chronic pancreatitis. World J Gastroenterol. 2008 May 28;14(20):3137-48. doi: 10.3748/wjg.14.3137.
Results Reference
background
PubMed Identifier
18373443
Citation
Katri KM, Ramadan BA, Mohamed FS. Thoracoscopic splanchnicectomy for pain control in irresectable pancreatic cancer. J Laparoendosc Adv Surg Tech A. 2008 Apr;18(2):199-203. doi: 10.1089/lap.2007.0066.
Results Reference
background
PubMed Identifier
26261731
Citation
Jones WB, Jordan P, Pudi M. Pain management of pancreatic head adenocarcinomas that are unresectable: celiac plexus neurolysis and splanchnicectomy. J Gastrointest Oncol. 2015 Aug;6(4):445-51. doi: 10.3978/j.issn.2078-6891.2015.052.
Results Reference
background
PubMed Identifier
23572221
Citation
Malec-Milewska MB, Tarnowski W, Ciesielski AE, Michalik E, Guc MR, Jastrzebski JA. Prospective evaluation of pain control and quality of life in patients with chronic pancreatitis following bilateral thoracoscopic splanchnicectomy. Surg Endosc. 2013 Oct;27(10):3639-45. doi: 10.1007/s00464-013-2937-0. Epub 2013 Apr 10.
Results Reference
background
PubMed Identifier
18556993
Citation
Davis BR, Vitale M, Lecompte M, Vitale D, Vitale GC. An objective study of pain relief in chronic pancreatitis from bilateral thoracoscopic splanchnicectomy. Am Surg. 2008 Jun;74(6):510-4; discussion 514-5.
Results Reference
background
Learn more about this trial
Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer
We'll reach out to this number within 24 hrs